Phase 2 N=215 Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
Atopic Dermatitis
Primary: Positive Anti-tetanus Response at Week 16 — 80; 73 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 Trial of Afatinib in Pediatric Tumours
Neuroectodermal Tumors · Rhabdomyosarcoma
Primary: Number of Participants With Objective Response - Maximum Tolerated Dose Expansion (MTD) Cohort — 3 Participants
Phase 2 N=1,235 A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
Respiratory Tract Infections
Primary: Sentinel Cohort: Percentage of Participants (Aged 18 to 49 Years) With Local Reactions Within 14 Days After Vaccination — 50.0; 58.3; 25.0; 75.0 Percentage of participants
Phase 2 N=75 Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
Hereditary Angioedema (HAE)
Primary: Number of Confirmed HAE Attacks — 0.519; 0.527; 0.249; 0.852 HAE attacks per week — p=<0.001
Phase 2 N=13 Effects of Salvinorin A on Brain Function
Drug Effect
Primary: Changes in Brain Activity (fMRI) as Assessed by Variance in BOLD Signal — 15.65; 18.06; 23.39; 8.93 variance in BOLD signal — p=.006
Phase 2 N=29 Low Dose Naltrexone for Chronic Pain From Arthritis
Osteoarthritis · Arthritis, Rheumatoid · Arthritis, Psoriatic
Primary: Brief Pain Inventory - Pain Interference — -23; -22 units on a scale — p=0.90
Phase 2 N=186 A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline to Week 8 in Mean Daily Average Pain Score Assessed by NRS — -1.26; -1.60 Units on a scale — p=0.086
Phase 2 N=12 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
Discoid Lupus Erythematosus
Primary: Cutaneous LE Diseases Area and Severity Index (CLASI) Score Based on Extent of Symptoms
Phase 2 N=90 IBUPAP Study for Pain Management in Children
Pain Management
Primary: Pain Score at 60 Minutes — 2.72; 3.10; 2.77 units on a scale
Phase 2 N=96 Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Squamous Cell Carcinoma of the Head and Neck · Carcinoma, Squamous Cell of the Head and Neck · Cancer of Head and Neck
Primary: Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site — 28; 8 Participants
Phase 2 N=47 Nabilone for Non-motor Symptoms in Parkinson's Disease
Parkinson Disease
Primary: Changes of Non-motor Symptoms — 1.00; 2.63 units on a scale
Phase 2 N=460 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 24.9; 25.4; 22.3; 23.7 percentage of participants
Phase 2 N=11 Carisbamate as a Potential Treatment for Alcohol Dependence
Alcohol Dependence · Alcohol Abuse · Substance Abuse
Primary: Mean Biphasic Alcohol Effects Scale (BAES) Scores — 27.5; 32.4; 23.0; 21.1 score on a scale
Phase 2 N=54 Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
Refractory Multiple Myeloma · Smoldering Multiple Myeloma · Stage I Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 1600 cGy
Phase 2 N=62 Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Objective Response — 22.5; 19.4; 11.3; 6.5 percentage of participants